Cue Biopharma (NASDAQ:CUE – Free Report) had its target price lowered by Piper Sandler from $8.00 to $3.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an overweight rating on the stock.
Several other brokerages also recently weighed in on CUE. Stifel Nicolaus reaffirmed a buy rating and set a $8.00 target price on shares of Cue Biopharma in a research note on Tuesday, April 9th. Oppenheimer restated an outperform rating and set a $10.00 price objective on shares of Cue Biopharma in a research report on Tuesday, April 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Cue Biopharma presently has a consensus rating of Buy and a consensus price target of $5.80.
View Our Latest Analysis on Cue Biopharma
Cue Biopharma Stock Down 3.5 %
Cue Biopharma (NASDAQ:CUE – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.05. The firm had revenue of $1.72 million during the quarter, compared to analyst estimates of $0.73 million. Cue Biopharma had a negative return on equity of 128.30% and a negative net margin of 711.84%. On average, research analysts expect that Cue Biopharma will post -0.97 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Navalign LLC purchased a new position in Cue Biopharma during the fourth quarter worth approximately $66,000. Legacy Capital Group California Inc. acquired a new stake in shares of Cue Biopharma during the fourth quarter valued at about $26,000. Wedmont Private Capital raised its position in Cue Biopharma by 100.0% in the first quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock valued at $76,000 after purchasing an additional 20,000 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Cue Biopharma by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares in the last quarter. 35.04% of the stock is owned by institutional investors and hedge funds.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
See Also
- Five stocks we like better than Cue Biopharma
- Health Care Stocks Explained: Why You Might Want to Invest
- Survey: Top 175 Fittest Retirement Locations in America
- Options Trading – Understanding Strike Price
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.